WHO: Plasma therapy for rehabilitation of new coronary pneumonia has not been proven effective or causes multiple side effects
On August 24, local time, the WHO held a routine press conference for the new crown pneumonia, aiming at the emergency use of the plasma of recovered patients with the new crown virus in the US authorized medical institutions to treat patients with new crowns. The chief scientist of the WHO Sumia Si Waminatan said that rehabilitation plasma therapy has a history of more than 100 years and has been used for different types of infectious diseases. It is effective for some diseases but has no effect on others. There have been many clinical trials of plasma therapy for rehabilitation of new coronary pneumonia around the world, but only a few have released the results, and the results have been mixed, and no consensus has been reached. At present, the quality of evidence is still very low. Therefore, WHO recommends that rehabilitation plasma therapy should still be used as an experimental therapy and continue to undergo clinical evaluation.
Sumia Swaminatan also pointed out that there are still some challenges in the practical application of rehabilitation plasma therapy. For example, the levels of antibodies carried by people infected with new coronary pneumonia after recovery are different and it is difficult to standardize. In addition, the number of hospitals that can implement this therapy and the number of donors are limited, but the most important question is whether the effectiveness and safety of the therapy can be confirmed in randomized trials.
Bruce Aylward, senior adviser to the Director-General of the World Health Organization, said that plasma rehabilitation therapy has a variety of side effects, from mild chills and fever, to more serious lung damage and even blood circulation overload. So the clinical trial results Vital. (Headquarters reporter Zhu He)